Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis

• Status: Completed
• Trial end date: 2011-09-30
• Target enrollment: 0
• Participant gender: All

Summary

roxithormycin 300 mg per day for 12 weeks could improve quality of life and physiological outcomes in bronchiectasis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prince of Songkla University
• Treatments: Roxithromycin

Criteria

minimum 15 year maximum 75 years

Criteria inclusion Criteria:

Symptomatic bronchiectasis Stable clinical bronchiectasis

Exclusion Criteria:

Adverse drug reaction to macrolide Recent exacerbation within 2 weeks History of macrolide therapy within 2 weeks active malignancy and end stage diseases 5. not perform lung function tests Females who were lactating